{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T07:46:26Z","timestamp":1791013586625,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,9,16]],"date-time":"2005-09-16T00:00:00Z","timestamp":1126828800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2005,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>New chemotherapy regimens for patients with colorectal cancer have improved survival, but at the cost of clinical toxicity. Oxaliplatin, an agent used in first-line therapy for metastatic colorectal cancer, causes acute and chronic neurotoxicity. This study was performed to carefully assess the incidence, type and duration of oxaliplatin neurotoxicity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A detailed questionnaire was completed after each chemotherapy cycle for patients with metastatic colorectal cancer enrolled in a phase I trial of oxaliplatin and capecitabine. An oxaliplatin specific neurotoxicity scale was used to grade toxicity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Eighty-six adult patients with colorectal cancer were evaluated. Acute neuropathy symptoms included voice changes, visual alterations, pharyngo-laryngeal dysesthesia (lack of awareness of breathing); peri-oral or oral numbness, pain and symptoms due to muscle contraction (spasm, cramps, tremors). When the worst neurotoxicity per patient was considered, grade 1\/2\/3\/4 dysesthesias and paresthesias were seen in 71\/12\/5\/0 and 66\/20\/7\/1 percent of patients. By cycles 3, 6, 9, and 12, oxaliplatin dose reduction or discontinuation was needed in 2.7%, 20%, 37.5% and 62.5% of patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Oxaliplatin-associated acute neuropathy causes a variety of distressing, but transient, symptoms due to peripheral sensory and motor nerve hyperexcitability. Chronic neuropathy may be debilitating and often necessitates dose reductions or discontinuation of oxaliplatin. Patients should be warned of the possible spectrum of symptoms and re-assured about the transient nature of acute neurotoxicity. Ongoing studies are addressing the treatment and prophylaxis of oxaliplatin neurotoxicity.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-5-116","type":"journal-article","created":{"date-parts":[[2005,9,16]],"date-time":"2005-09-16T18:13:57Z","timestamp":1126894437000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":141,"title":["Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer"],"prefix":"10.1186","volume":"5","author":[{"given":"Gregory D","family":"Leonard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice A","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary G","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Fioravanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Harold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca R","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean L","family":"Grem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,9,16]]},"reference":[{"key":"304_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3322\/canjclin.54.1.8","volume":"54","author":"A Jemal","year":"2004","unstructured":"Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ, American Cancer Society: Cancer Statistics, 2004. CA Cancer J Clin. 2004, 54: 8-29.","journal-title":"CA Cancer J Clin"},{"key":"304_CR2","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1023\/A:1008347829017","volume":"10","author":"S Giacchetti","year":"1999","unstructured":"Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F, Brienza S, Alafaci E, Bertheault-Cvitkovic F, Jasmin C, Reynes M, Bismuth H, Misset JL, Levi F: Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol. 1999, 10: 663-669. 10.1023\/A:1008347829017.","journal-title":"Ann Oncol"},{"key":"304_CR3","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","volume":"18","author":"A De Gramont","year":"2000","unstructured":"De Gramont A, Figer M, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000, 18: 2938-2947.","journal-title":"J Clin Oncol"},{"key":"304_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1200\/JCO.2004.09.046","volume":"22","author":"RM Goldberg","year":"2004","unstructured":"Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts S: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004, 22: 23-30. 10.1200\/JCO.2004.09.046.","journal-title":"J Clin Oncol"},{"key":"304_CR5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","volume":"22","author":"C Tournigand","year":"2004","unstructured":"Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A: OLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004, 22: 229-237. 10.1200\/JCO.2004.05.113.","journal-title":"J Clin Oncol"},{"key":"304_CR6","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1023\/A:1008334215414","volume":"10","author":"S Faivre","year":"1999","unstructured":"Faivre S, Kalla S, Cvitkovic E, Bourdon O, Hauteville D, Dourte LM, Bensmaine MA, Itzhaki M, Marty M, Extra JM: Oxaliplatin and paclitaxel combination in patients with platinum- pretreated ovarian carcinoma: an investigator-originated compassionate- use experience. Ann Oncol. 1999, 10: 1125-1128. 10.1023\/A:1008334215414.","journal-title":"Ann Oncol"},{"key":"304_CR7","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1200\/JCO.2002.08.050","volume":"20","author":"C Kollmannsberger","year":"2002","unstructured":"Kollmannsberger C, Rick O, Derigs HG, Schoeffski P, Metzner B, Hartmann JT, Rick O, Stengele K, Hohloch K, Spott C, Kanz L, Bokemeyer C: Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol. 2002, 20: 2031-2037. 10.1200\/JCO.2002.08.050.","journal-title":"J Clin Oncol"},{"issue":"Suppl 11","key":"304_CR8","first-page":"33","volume":"14","author":"PM Lorusso","year":"2000","unstructured":"Lorusso PM: Oxaliplatin in tumors other than colorectal cancer. Oncology (Huntingt). 2000, 14 (Suppl 11): 33-37.","journal-title":"Oncology (Huntingt)"},{"issue":"Supp 15","key":"304_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1053\/sonc.2002.35525","volume":"29","author":"E Gamelin","year":"2002","unstructured":"Gamelin E, Gamelin L, Bossi L, Quasthoff S: Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol. 2002, 29 (Supp 15): 21-33. 10.1053\/sonc.2002.35525.","journal-title":"Semin Oncol"},{"issue":"Suppl 15","key":"304_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0093-7754(03)00399-3","volume":"30","author":"A Grothey","year":"2003","unstructured":"Grothey A: Oxaliplatin-safety profile: neurotoxicity. Semin Oncol. 2003, 30 (Suppl 15): 5-13.","journal-title":"Semin Oncol"},{"key":"304_CR11","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1200\/JCO.2002.07.056","volume":"20","author":"RH Wilson","year":"2002","unstructured":"Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL: Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol. 2002, 20: 1767-1774. 10.1200\/JCO.2002.07.056.","journal-title":"J Clin Oncol"},{"key":"304_CR12","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/mus.10559","volume":"29","author":"TJ Lehky","year":"2004","unstructured":"Lehky TJ, Leonard GD, Wilson RH, Grem JL Floeter MK: Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle and Nerve. 2004, 29: 387-392. 10.1002\/mus.10559.","journal-title":"Muscle and Nerve"},{"key":"304_CR13","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1152\/jn.2001.85.5.2293","volume":"85","author":"F Grolleau","year":"2001","unstructured":"Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Gamelin E: A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol. 2001, 85: 2293-2297.","journal-title":"J Neurophysiol"},{"key":"304_CR14","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1006\/toxs.1998.2558","volume":"46","author":"J Holmes","year":"1998","unstructured":"Holmes J, Stanko J, Varchenko , Ding H, Madden VJ, Bagnell CR, Wyrick SD, Chaney SG: Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. Toxicol Sci. 1998, 46: 342-351. 10.1006\/toxs.1998.2558.","journal-title":"Toxicol Sci"},{"key":"304_CR15","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1016\/S0959-8049(01)00300-8","volume":"37","author":"G Cavaletti","year":"2001","unstructured":"Cavaletti G, Tredici G, Petruccioli MG, Donde E, Tredici P, Marmiroli P, Minoia C, Ronchi A, Bayssas M, Etienne GG: Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer. 2001, 37: 2457-2463. 10.1016\/S0959-8049(01)00300-8.","journal-title":"Eur J Cancer"},{"key":"304_CR16","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1097\/01.cad.0000136883.27176.88","volume":"15","author":"GD Leonard","year":"2004","unstructured":"Leonard GD, Wagner MR, Quinn MG, Grem JL: Severe disabling sensory-motor polyneuropathy during oxaliplatin-based chemotherapy. Anticancer Drugs. 2004, 15: 733-735. 10.1097\/01.cad.0000136883.27176.88.","journal-title":"Anticancer Drugs"},{"key":"304_CR17","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1056\/NEJMoa032709","volume":"350","author":"T Andre","year":"2004","unstructured":"Andre T, Boni C, Mounedji-Boudiaf L, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A, Multicenter International Study of Oxaliplatin\/5-Fluorouracil\/Leucovorin in the Adjuvant Treatment of Colon Cancer(MOSAIC) Investigators: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. New Eng J Med. 2004, 350: 2343-2451. 10.1056\/NEJMoa032709.","journal-title":"New Eng J Med"},{"key":"304_CR18","first-page":"276","volume":"22","author":"JN Atkins","year":"2003","unstructured":"Atkins JN, Jacobs S, Wieand S, Smith R, John W, Renshaw G, Colangelo L, Geyer C, Wolmark N: Pemetrexed and oxaliplatin for first-line treatment of patients with advanced colorectal cancer: A phase II trial of the NSABP foundation research program. Proc Am Soc Clin Oncol. 2003, 22: 276-abstr 1108","journal-title":"Proc Am Soc Clin Oncol"},{"key":"304_CR19","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1093\/annonc\/mdf091","volume":"13","author":"S Cascinu","year":"2002","unstructured":"Cascinu S, Graziano F, Ferrau F, Catalano V, Massacesi C, Santini D, Silva RR, Barni S, Zaniboni A, Battelli N, Siena S, Giordani P, Mari D, Baldelli AM, Antognoli S, Maisano R, Priolo D, Pessi MA, Tonini G, Rota S, Labianca R: alitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the study of gastrointestinal tract carcinomas (GISCAD). Ann Oncol. 2002, 13: 716-720. 10.1093\/annonc\/mdf091.","journal-title":"Ann Oncol"},{"key":"304_CR20","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1200\/JCO.2002.07.087","volume":"20","author":"MM Borner","year":"2002","unstructured":"Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M, Herrmann R, Pestalozzi BC, Saletti P, Hanselmann S, Muller S, Brauchli P, Castiglione-Gertsch M, Goldhirsch A, Roth AD: Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol. 2002, 20: 1759-1766. 10.1200\/JCO.2002.07.087.","journal-title":"J Clin Oncol"},{"key":"304_CR21","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1200\/JCO.2004.11.069","volume":"22","author":"J Cassidy","year":"2004","unstructured":"Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, Debraud F, Figer A, Grossmann J, Sawada N, Schoffski P, Sobrero A, Van Cutsem E, Diaz-Rubio E: XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol. 2004, 22: 2084-2091. 10.1200\/JCO.2004.11.069.","journal-title":"J Clin Oncol"},{"key":"304_CR22","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/cncr.11925","volume":"100","author":"AF Shields","year":"2004","unstructured":"Shields AF, Zalupski MM, Marshall JL, Meropol NJ: Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial. Cancer. 2004, 100: 531-537. 10.1002\/cncr.11925.","journal-title":"Cancer"},{"key":"304_CR23","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1093\/annonc\/mdg360","volume":"14","author":"M Zeuli","year":"2003","unstructured":"Zeuli M, Nardoni C, Pino MS, Gamucci T, Gabriele A, Ferraresi V, Giannarelli D, Cognetti F: Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. Ann Oncol. 2003, 14: 1378-1382. 10.1093\/annonc\/mdg360.","journal-title":"Ann Oncol"},{"key":"304_CR24","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1200\/JCO.2003.09.016","volume":"21","author":"W Scheithauer","year":"2003","unstructured":"Scheithauer W, Kornek GV, Raderer M, Schull B, Schmid K, Kovats E, Schneeweiss B, Lang F, Lenauer A, Depisch D: Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2003, 21: 1307-1312. 10.1200\/JCO.2003.09.016.","journal-title":"J Clin Oncol"},{"key":"304_CR25","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1093\/jnci\/86.21.1608","volume":"86","author":"FA Levi","year":"1994","unstructured":"Levi FA, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiuolo R, Chollet P, Garufi C, Itzhaki M, Dogliotti L: Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst. 1994, 86: 1608-1617.","journal-title":"J Natl Cancer Inst"},{"key":"304_CR26","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2000.18.1.136","volume":"18","author":"S Giacchetti","year":"2000","unstructured":"Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F: Phase III multicenter randomized trail of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000, 18: 136-147.","journal-title":"J Clin Oncol"},{"key":"304_CR27","first-page":"129a","volume":"21","author":"A Grothey","year":"2002","unstructured":"Grothey A, Deschler B, Kroenig H, Ridwelski K, Reichardt P, Kretzschmar A, Clemens M, Hirschmann W, Lorenz M, Asperger W, Buechele T, Schmoll H-J: Phase III study of bolus 5-fluorouracil (5-FU)\/folinic acid (FA) (Mayo) vs weekly high-dose 24 h 5-FU infusion\/FA+oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol. 2002, 21: 129a-abstr 512","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"14S","key":"304_CR28","first-page":"256s","volume":"22","author":"HT Arkenau","year":"2004","unstructured":"Arkenau HT, Schmoll H, Kubicka S, Seufferlein T, Reichardt P, Freier W, Graeven U, Grothey A: Phase III trial of infusional 5-fluorouracil\/folinic acid plus oxaliplatin versus capecitabine plus oxaliplatin as first line treatment in advanced colorectal carcinoma: Results of an interim safety analysis. Proc Am Soc Clin Oncol. 2004, 22 (14S): 256s-abstract 3546","journal-title":"Proc Am Soc Clin Oncol"},{"key":"304_CR29","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1200\/JCO.2003.11.126","volume":"21","author":"ML Rothenberg","year":"2003","unstructured":"Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a Phase III trial. J Clin Oncol. 2003, 21: 2059-2069. 10.1200\/JCO.2003.11.126.","journal-title":"J Clin Oncol"},{"key":"304_CR30","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3816\/CCC.2002.n.011","volume":"2","author":"C Lersch","year":"2002","unstructured":"Lersch C, Schmelz R, Eckel F, Erdmann J, Mayr M, Schulte-Frohlinde E, Quasthoff S, Grosskreutz J, Adelsberger H: Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer. Clin Colorectal Cancer. 2002, 2: 54-58.","journal-title":"Clin Colorectal Cancer"},{"key":"304_CR31","first-page":"609a","volume":"19","author":"G Mariani","year":"2000","unstructured":"Mariani G, Garrone O, Granetto C, Numico G, LaCiura P, Grecchi G, DiCostanzo G, Merlano M: Oxaliplatin induced neuropathy: could gabapentin be the answer?. Proc Am Soc Clin Oncol. 2000, 19: 609a-abstr 2397","journal-title":"Proc Am Soc Clin Oncol"},{"key":"304_CR32","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-03-0666","volume":"10","author":"L Gamelin","year":"2004","unstructured":"Gamelin L, Boisdron-Celle M, Delva R, Guerin-Meyer V, Ifrah N, Morel A, Gamelin E: Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res. 2004, 10: 4055-4061. 10.1158\/1078-0432.CCR-03-0666.","journal-title":"Clin Cancer Res"},{"key":"304_CR33","first-page":"297s","volume":"22","author":"S Pederiva","year":"2004","unstructured":"Pederiva S, Caspar CB: Management of acute oxaliplatin-related peripheral sensory neuropathy with magnesium and calcium. Proc Am Soc Clin Oncol. 2004, 22: 297s-abstr 3715","journal-title":"Proc Am Soc Clin Oncol"},{"key":"304_CR34","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1200\/JCO.2002.07.061","volume":"20","author":"S Cascinu","year":"2002","unstructured":"Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, Baldelli AM, Beretta GD, Ubiali E, Catalano G: Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: A randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2002, 20: 3478-3483. 10.1200\/JCO.2002.07.061.","journal-title":"J Clin Oncol"},{"key":"304_CR35","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1200\/JCO.2002.99.502","volume":"20","author":"C Gedlicka","year":"2002","unstructured":"Gedlicka C, Scheithauer W, Schull B, Kornek GV: Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. J Clin Oncol. 2002, 20: 3359-3360. 10.1200\/JCO.2002.99.502. (letter)","journal-title":"J Clin Oncol"},{"key":"304_CR36","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1023\/A:1011184609963","volume":"12","author":"M Penz","year":"2001","unstructured":"Penz M, Kornek GV, Raderer H, Ulrich-Pur H, Fiebiger W, Scheithauer W: Subcutaneous administration of amifostine: A promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy. Ann Oncol. 2001, 12: 421-422. 10.1023\/A:1011184609963.","journal-title":"Ann Oncol"},{"key":"304_CR37","first-page":"302b","volume":"20","author":"S Rudolph","year":"2001","unstructured":"Rudolph S, Fahlke J, Fenchel K, Fenchel K, Lippert H, Ridwelski K: Randomized trial with or without amifostine to reduce neurotoxic side effects under chemotherapy with oxaliplatin (L-OHP), FA\/5-FU. Proc Am Soc Clin Oncol. 2001, 20: 302b-abstr 2958","journal-title":"Proc Am Soc Clin Oncol"},{"key":"304_CR38","first-page":"362","volume":"22","author":"J Preiss","year":"2003","unstructured":"Preiss J, Meisel O: Successful auricular neural therapy in oxaliplatin-induced sensory neuropathy. Proc Am Soc Clin Oncol. 2003, 22: 362-abstr 1454","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"14S","key":"304_CR39","first-page":"270s","volume":"22","author":"RD Afafitei","year":"2004","unstructured":"Afafitei RD, Schneider S, Iqbal S, Yang D, Groshen S, Lenz HJ: Effect of celecoxib on neurotoxicity in patients with metastatic colorectal cancer treated with 5-FU\/oxaliplatin. Proc Am Soc Clin Oncol. 2004, 22 (14S): 270s-abstract 3600","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"14S","key":"304_CR40","first-page":"251s","volume":"22","author":"A De Gramont","year":"2004","unstructured":"De Gramont A, Cervantes G, Andre T, Figer A, Lledo G, Flesch M, Mineur L, Russ G, Quinaux E, Etienne P-L: OPTIMOX study: FOLFOX7\/LV5FU2 compared to FOLFOX 4 in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol. 2004, 22 (14S): 251s-abstr 3525","journal-title":"Proc Am Soc Clin Oncol"},{"key":"304_CR41","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/00000421-199806000-00008","volume":"21","author":"ME Stein","year":"1998","unstructured":"Stein ME, Drumea K, Yarnitsky D, Benny A, Tzuk-Shina T: A rare event of 5-fluorouracil-associated peripheral neuropathy: a report of two patients. Am J Clin Oncol. 1998, 21: 248-249. 10.1097\/00000421-199806000-00008.","journal-title":"Am J Clin Oncol"},{"key":"304_CR42","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1097\/00001813-200107000-00006","volume":"12","author":"MW Saif","year":"2001","unstructured":"Saif MW, Wilson RH, Harold N, Keith B, Dougherty DS, Grem JL: Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil. Anti-Cancer Drugs. 2001, 12: 525-531. 10.1097\/00001813-200107000-00006.","journal-title":"Anti-Cancer Drugs"},{"key":"304_CR43","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/00001813-200409000-00005","volume":"15","author":"MW Saif","year":"2004","unstructured":"Saif MW, Wood TE, McGee PJ, Diasio RB: Peripheral neuropathy associated with capecitabine. Anti-Cancer Drugs. 2004, 15: 767-771. 10.1097\/00001813-200409000-00005.","journal-title":"Anti-Cancer Drugs"},{"key":"304_CR44","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3816\/CCC.2003.n.019","volume":"3","author":"LS Couch","year":"2003","unstructured":"Couch LS, Groteluschen DL, Stewart JA, Mulkerin DL: Capecitabine-related neurotoxicity presenting as trismus. Clin Colorectal Cancer. 2003, 3: 121-123.","journal-title":"Clin Colorectal Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-5-116.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-5-116\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-5-116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-5-116.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T21:58:22Z","timestamp":1630447102000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-5-116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9,16]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["304"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-5-116","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9,16]]},"assertion":[{"value":"29 April 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2005","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2005","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"116"}}